PF-07314470 / Pfizer - LARVOL DELTA

STAT3 phosphorylation as an endpoint in a functional cell-based neutralizing antibody assay with potential for broad application. (PubMed, Bioanalysis) - "Experiments demonstrated the feasibility of a cell-based NAb assay for PF-07314470. The assay system could be used for other biotherapeutics that modulate pSTAT3."

Journal

A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: Pfizer | N=103 ➔ 23 | Trial completion date: Jun 2026 ➔ Aug 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Aug 2025; The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination